glp-1-ra Indications for GLP-1/GIP RA Summary Sheet and Beyond! 🔸 Should GLP-1 RAs be

These medications help reduce appetite, improve satiety, and support sustainable weight loss when combined with healthy lifestyle habits

Risk vs

We still catch the errors

Food and Drug Administration (FDA) has now approved two oral GLP-1 drugs: an oral version of Novo Nordisks Wegovy at the end of 2025, and Eli Lillys daily, non-peptide pillorforglipron, a distinct competitor to oral semaglutide and different from Eli Lillys injectable tirzepatidecalled Foundayo in April, which is notable because it can be taken without restrictions on timing or food or water intake

The guidance is in response to recent case reports and large case series that have shown a risk of retained gastric contents and cases of pulmonary aspiration during sedation for endoscopic procedures or general anaesthesia in individuals treated with GLP-1RAs or GLP-1/GIPRAs

We strive to make sustainable weight loss attainable and tailored to the individual